Structure Therapeutics (GPCR) Stock Forecast & Price Target

$41.75

+0.22 (+0.53%)

(As of 09/27/2024 ET)

Structure Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 8 Analyst Ratings

Sell
0

Hold
0

Buy
8

Based on 8 Wall Street analysts who have issued ratings for Structure Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 8 have given a buy rating for GPCR.

Consensus Price Target

$88.33
111.58% Upside

According to the 8 analysts' twelve-month price targets for Structure Therapeutics, the average price target is $88.33. The highest price target for GPCR is $118.00, while the lowest price target for GPCR is $65.00. The average price target represents a forecasted upside of 111.58% from the current price of $41.75.

GPCR Analyst Ratings Over Time

Type	Current Forecast 9/29/23 to 9/28/24	1 Month Ago 8/30/23 to 8/29/24	3 Months Ago 7/1/23 to 6/30/24	1 Year Ago 9/29/22 to 9/29/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$88.33	$84.63	$85.25	$59.50
Forecasted Upside	111.58% Upside	120.84% Upside	117.09% Upside	18.01% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Massive NVIDIA Sell-Off: Are We Headed for a Market Collapse? (Ad)

You may have heard about NVIDIA's CEO dumping shares of his own company. He sold 4.4 million shares this year. But here's what's even more concerning...

Click here for his urgent warning - and 4 steps you need to take today to protect your retirement to

GPCR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GPCR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Structure Therapeutics Stock vs. The Competition

Type	Structure Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.78	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	111.58% Upside	818.48% Upside	6.14% Upside
News Sentiment Rating	Positive News See Recent GPCR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/23/2024	Cantor Fitzgerald 3 of 5 stars	P. Agrawal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00 ➝ $65.00	+55.06%
9/23/2024	Morgan Stanley 3 of 5 stars		Initiated Coverage	Overweight	$118.00	+181.49%
8/9/2024	JMP Securities 2 of 5 stars		Lower Target	Market Outperform ➝ Market Outperform	$91.00 ➝ $86.00	+157.02%
6/7/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$83.00 ➝ $100.00	+86.64%
5/21/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$65.00	+81.67%
2/27/2024	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Belghiti Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
Jovine Was Right in 2008—Will You Listen This Time? (Ad) The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future. Take these 4 steps today to protect your retirement NOW
10/26/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$58.00 ➝ $93.00	+32.38%
10/2/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$50.00 ➝ $92.00	+58.76%
9/29/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$46.00 ➝ $97.00	+92.38%
9/29/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$50.00 ➝ $79.00	+58.35%
2/28/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$33.00	+37.50%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:05 PM ET.

GPCR Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Structure Therapeutics is $88.33, with a high forecast of $118.00 and a low forecast of $65.00.
: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Structure Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GPCR shares.
: According to analysts, Structure Therapeutics's stock has a predicted upside of 111.58% based on their 12-month stock forecasts.
: Structure Therapeutics has been rated by research analysts at Cantor Fitzgerald, JMP Securities, and Morgan Stanley in the past 90 days.
: Analysts like Structure Therapeutics more than other "medical" companies. The consensus rating for Structure Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GPCR compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)

The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.

Take these 4 steps today to protect your retirement NOW

This page (NASDAQ:GPCR) was last updated on 9/28/2024 by MarketBeat.com Staff

From Our Partners